DPP-IV resistance is achieved through an -aminoisobutyric acid (Aib) substitution at position 2, blocking the proteolytic cleavage that normally inactivates incretin peptides within minutes of secretion
This discussion should address: Your specific diabetes control needs and whether alternative medications could provide adequate glycemic management The infant's health status , as premature or medically fragile infants may warrant more conservative medication approaches Your breastfeeding goals , including whether you plan exclusive breastfeeding or combination feeding Monitoring strategies for both maternal blood sugar control and infant growth and development Contact your healthcare provider if you experience severe or persistent side effects while taking any diabetes medication during lactation, including nausea, vomiting, diarrhea, or signs of hypoglycemia (shakiness, sweating, confusion)
It promotes neuroplasticity in brain regions like the hippocampus by increasing BDNF levels, glutamate release, and upregulating mGLU2 receptors, particularly in the hippocampus and prefrontal cortex
Association of Glucagon-Like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases
The needle is really small